A license agreement has been reached between Alligator Bioscience with Biotheus Inc., a Chinese company based in Guangdong, China. Under the license agreement, Alligator has granted Biotheus rights in Greater China (including Republic of China, Hongkong, Taiwan and Macau) to an antibody from ALLIGATOR-GOLD® for the creation of up to three bispecific molecules. It also gives the possibility of expanding the license to covering global rights.
Biotheus is a fast-growing biotechnology company based in Zhuhai, Guangdong, China with expectations to expand to >60 employees by 2019. Biotheus’ management team has broad experience from drug discovery to NDA filing in China. Biotheus is developing a broad me-better/novel target pipeline focused on immuno-oncology and metabolic disease areas, with the aim to develop their leading assets towards market authorization. Biotheus is actively looking for late-stage clinical and commercialization partners to fulfill these aims.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees.